Lantheus' F-18 PET agent shows good dosing ratio

Jun 10, 2010

Preliminary phase II data suggest the uptake properties of Lantheus Medical Imaging's investigational PET agent flurpiridaz F-18 injection allow for a relatively low dosing ratio and a delay of 30 to 60 minutes between rest and stress injections, depending on the mode of stress used.

Flurpiridaz F-18 is in development for use with PET for myocardial perfusion imaging (MPI) to detect coronary artery disease.

The North Billerica, MA-based company's study, presented on June 8 at the annual SNM meeting, describes the methodology used to define an imaging protocol for a one-day rest-stress MPI test using the PET imaging agent, formerly known as BMS747158.

Lantheus is partnering with Cardiovascular Imaging Technologies of Kansas City, MO, to develop the technique to determine the dependence of the rest-to-stress dosing ratio to identify the minimum delay between the two injections for a one-day rest-stress test.

Lantheus reports F-18 cardiac PET findings, June 7, 2010

Lantheus inks Ablavar contract with Amerinet, June 3, 2010

Lantheus receives Mo-99 from Europe, May 21, 2010

Lantheus touts SNM papers, May 19, 2010

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$